Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy in the Long Term Management of HIV Infection (PIVOT) (PIVOT)
![]() |
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. |
ClinicalTrials.gov Identifier: NCT01230580 |
Recruitment Status
: Unknown
Verified October 2010 by Medical Research Council.
Recruitment status was: Active, not recruiting
First Posted
: October 29, 2010
Last Update Posted
: October 10, 2012
|
- Study Details
- Tabular View
- No Results Posted
- Disclaimer
- How to Read a Study Record
Condition or disease | Intervention/treatment | Phase |
---|---|---|
HIV Infection Acquired Immunodeficiency Syndrome | Drug: Protease Inhibitor Drug: Standard-of-care Antiretroviral therapy | Phase 4 |
Study Type : | Interventional (Clinical Trial) |
Actual Enrollment : | 587 participants |
Allocation: | Randomized |
Intervention Model: | Parallel Assignment |
Masking: | None (Open Label) |
Primary Purpose: | Treatment |
Official Title: | A Randomised Controlled Trial of a Strategy of Switching to Boosted PI Monotherapy Versus Continuing Combination ART for the Long-term Management of HIV-1 Infected Patients Who Have Achieved Sustained Virological Suppression on HAART |
Study Start Date : | November 2008 |
Estimated Primary Completion Date : | November 2013 |
Estimated Study Completion Date : | November 2013 |

Arm | Intervention/treatment |
---|---|
Experimental: Protease Inhibitor Monotherapy
Ritonavir-boosted protease inhibitor
|
Drug: Protease Inhibitor
Switch to a regimen comprising a single ritonavir-boosted Protease Inhibitor
|
Active Comparator: Control
Standard-of-care triple-therapy regimen
|
Drug: Standard-of-care Antiretroviral therapy
Regimen should consist of 3 drugs: 2 nucleoside reverse transcriptase inhibitors with either a non-nucleoside reverse transcriptase inhibitor or a protease inhibitor
|
- Loss of future drug options [ Time Frame: Up to 5 years ]The first occurrence of intermediate to high level resistance to any one or more of the standard antiretroviral drugs (limited to licensed drugs in contemporary use) to which the patient's virus was considered to be sensitive at trial entry (i.e. excluding drug resistance that was known to be present on previous resistance testing).
- Death from any cause [ Time Frame: Up to 5 years ]
- Serious AIDS-defining illness [ Time Frame: Up to 5 years ]
- Serious non-AIDS defining illness [ Time Frame: Up to 5 years ]
- Adverse events [ Time Frame: Up to 5 years ]
- Confirmed Virological rebound [ Time Frame: Up to 5 years ]
- CD4+ count change [ Time Frame: Up to 5 years ]
- Health-related Quality of Life change [ Time Frame: Up to 5 years ]
- Neurocognitive function change [ Time Frame: Up to 5 years ]
- Cardiovascular risk change [ Time Frame: Up to 5 years ]
- Health care costs [ Time Frame: Up to 5 years ]
- HIV VL in Genital Secretions [ Time Frame: Week 96 ]
In a sub-set of participants (n=73):-
- Compare prevalence of detectable VL and magnitude of viral replication in genital secretions in patients taking PI monotherapy and triple therapy; to test if PI monotherapy is non-inferior to triple therapy.
- Compare drug levels in genital secretions and plasma.
- Describe the profile of drug resistance (if any) in patients with detectable VL in genital secretions and to compare this with any previous or subsequent resistance profile in plasma.
(Genital Secretions substudy REC # 09/H0305/58)
- HIV VL in CSF [ Time Frame: Week 96 ]
In a subset of participants on PI monotherapy (n=40).
- Estimate the proportion of patients who have detectable HIV viral load in CSF after 48 weeks on PI monotherapy, and to refute the hypothesis that this proportion is greater than 20%.
- Assess whether CSF markers of CNS immune activation, inflammation and neuronal degeneration are elevated after 48 weeks on PI monotherapy.
- Assess whether CSF HIV viral load and markers of immune activation, inflammation and neuronal degeneration are elevated in patients with symptomatic CNS disease.
(CNS substudy REC # 09/H0305/58).

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study: | 18 Years and older (Adult, Senior) |
Sexes Eligible for Study: | All |
Accepts Healthy Volunteers: | No |
Inclusion Criteria:
Vl < 50 for 24 weeks prior to screening CD4 > 100 at screening
Exclusion Criteria:
- Known major protease resistance mutation(s) documented on prior resistance testing if performed (prior resistance testing is not mandatory for trial participation).
- Previous change in ART drug regimen for reasons of unsatisfactory virological response (patients who have changed regimen for prevention or management of toxicity or to improve regimen convenience are permitted to enter the trial).
- Previous allergic reaction to a PI.
- Patient currently using or likely to require use of concomitant medication with known interaction with PIs.
- Patient requiring treatment with radiotherapy, cytotoxic chemotherapy, or is anticipated to need these during the trial period.
- Treatment for acute opportunistic infection within 3 months prior to trial screening.
- Pregnant or trying to become pregnant at the time of trial entry.
- History of active substance abuse or psychiatric illness that, in the opinion of the investigator, would preclude compliance with the protocol, dosing schedule or assessments.
- History of HIV encephalopathy with current deficit >1 in any domain of the Neuropsychiatric AIDS Rating Scale (see Appendix 7).
- Past or current history of cardiovascular disease, or 10 year absolute coronary heart disease risk of >30%, or risk of >20% if the patient has diabetes or a family history of premature ischaemic heart disease or stroke.
- History of insulin-dependent diabetes mellitus.
- Patient currently receiving interferon therapy for Hepatitis C virus infection or planning to start treatment for Hepatitis C at the time of trial entry.
- Co-infection with hepatitis B, defined as Hepatitis BsAg positive at screening or at any time since HIV diagnosis, unless the patient has had a documented Hepatitis B DNA measurement of less than 1000 copies/ml taken whilst off Hepatitis B active drugs.
- Any other active clinically significant condition, or findings during screening medical history or examination, or abnormality on screening laboratory blood tests that would, in the opinion of the investigator, compromise the patient's safety or outcome in the trial.
- Fasting plasma glucose >7.0mmol/L at trial screening.

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01230580
Principal Investigator: | Nick Paton, MD | Medical Research Council |
Publications automatically indexed to this study by ClinicalTrials.gov Identifier (NCT Number):
Responsible Party: | Medical Research Council (Dr Nick Paton Chief Investigator MRC Clinical Trials Unit), Medical Research Council |
ClinicalTrials.gov Identifier: | NCT01230580 History of Changes |
Other Study ID Numbers: |
PIVOT 2007-006448-23 ( EudraCT Number ) |
First Posted: | October 29, 2010 Key Record Dates |
Last Update Posted: | October 10, 2012 |
Last Verified: | October 2010 |
Keywords provided by Medical Research Council:
Protease Inhibitors RNA virus infections Virus diseases Sexually Transmitted Diseases viral |
Immune system diseases Anti-infective Agents Drug resistance |
Additional relevant MeSH terms:
Infection Communicable Diseases HIV Infections Acquired Immunodeficiency Syndrome Immunologic Deficiency Syndromes Lentivirus Infections Retroviridae Infections RNA Virus Infections Virus Diseases Sexually Transmitted Diseases, Viral Sexually Transmitted Diseases |
Immune System Diseases Slow Virus Diseases Protease Inhibitors HIV Protease Inhibitors Enzyme Inhibitors Molecular Mechanisms of Pharmacological Action Anti-HIV Agents Anti-Retroviral Agents Antiviral Agents Anti-Infective Agents |